• Optimi Health named Michael Blough as chief clinical development officer in a newly created role.
• Blough previously led Health Canada-authorized clinical trials evaluating psilocybin and MDMA for mental health conditions.
• He will oversee clinical development strategy for a planned Phase 2 psilocybin trial in major depressive disorder.
• He will also lead execution of a planned Phase 3 MDMA trial in PTSD, including site activation and trial datasets.
• The company expects both trials to begin enrolling patients next year.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Optimi Health Corp. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-006164), on September 22, 2026, and is solely responsible for the information contained therein.